(Total Views: 80)
Posted On: 12/06/2024 3:49:05 AM
Post# of 499
2025 the UEEC merger year at least with the Trump forecast....
https://www.biospace.com/mergers-acquisitions
“The administration is expected to usher in a new era of a less restrictive FTC, which will likely result in increased M&A activity ,” Baird senior research analyst Mike Perrone told BioSpace by email. This, he added, would be most welcome, noting that 2024 is “the first year in recent memory that has not seen a biopharma transaction above $5B in value. . . . Ultimately any increase in large biopharma M&A would be a boost to SMID cap biotech valuations.”
More deals, according to S&P, would be “a positive for an industry that needs M&A.”
Stay tuned to long term investors and a capital influx!
$5-$10+
https://www.biospace.com/mergers-acquisitions
“The administration is expected to usher in a new era of a less restrictive FTC, which will likely result in increased M&A activity ,” Baird senior research analyst Mike Perrone told BioSpace by email. This, he added, would be most welcome, noting that 2024 is “the first year in recent memory that has not seen a biopharma transaction above $5B in value. . . . Ultimately any increase in large biopharma M&A would be a boost to SMID cap biotech valuations.”
More deals, according to S&P, would be “a positive for an industry that needs M&A.”
Stay tuned to long term investors and a capital influx!
$5-$10+
(0)
(0)Scroll down for more posts ▼
